.After a handful of years in biotech, Mike Quigley, Ph.D., is returning to the pharma crease, using up the leading scientific research area at Sanofi.Quigley is going to start Sept. 30 as the French Big Pharma's main medical policeman and worldwide head of research, Sanofi told Ferocious Biotech in an emailed statement.Quigley is actually replacing Frank Nestle, M.D., that left Sanofi this spring season among a worldwide overhaul of the provider's R&D unit. Nestle, who invested 8 years along with the pharma, dove over to Deerfield Control, where he currently acts as a companion on the therapies team as well as chief executive officer of the agency's therapeutic discovery and growth functions.
Quigley will join Sanofi from a San Francisco-based biotech that remains in secrecy, according to his LinkedIn profile. He is actually currently detailed as the firm's founder, head of state as well as chief executive officer.Because August 2021, Quigley has acted as a venture companion at SV Health Investors, a medical care fund manager with existing assets in biotechs such as BioAge, Cerevance, Dualitas Therapies and also Nimbus Rehabs, to name a few. Quigley previously stored the leading place at Dualitas, a biotech that continues to be in secrecy, depending on to STAT.The future Sanofi leader also earlier helmed Therini Bio, an immunotherapy biotech operating to build procedures for neurodegenerative illness steered through vascular problems.Before investing the final couple of years in biotech, Quigley possesses an also longer track record in Huge Pharma, most just recently serving as Gilead's senior vice head of state of investigation the field of biology till the summer season of 2021. Just before that, he clocked in more than four years around different management parts at Bristol Myers Squibb and also acted as a medical director at Johnson & Johnson's Janssen arm prior to that.Sanofi stated Quigley's objective in his new part will be actually to "maximize our possibility of success through superior collaborations all over our company as well as past, delivering best-in-class technology as well as cultivating and also sourcing brand-new industry-leading talent along with a dedication to range," according to an internal memorandum obtained by STAT.